[Recent acquisitions in the treatment of chronic immune-mediated polyneuropathies].
Chronic immune-mediated polyneuropathies encompass chronic inflammatory demyelinating polyneuropathies, polyneuropathies associated with monoclonal gammopathy and multifocal motor neuropathy with persistent conduction blocks. Their diagnosis is made on clinical, electrophysiological and sometimes immunochemical and pathological criteria. The efficacy of intravenous immunoglobulins has been reported in the short-term treatment of these neuropathies in the same way than corticosteroids and plasma exchanges, depending on the type of the polyneuropathy. The efficacy of long-term treatments needs further evaluation.
Léger
J-M
JM
Groupe Neuropathies Périphériques Pitié-Salpêtrière (GNPS), Hôpital de la Pitié-Salpêtrière, Paris. jean-marc.leger@psl.ap-hop-paris.fr
Viala
K
K
D020274:Autoimmune Diseases of the Nervous System / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D005544:Forecasting; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007166:Immunosuppressive Agents; D009069:Movement Disorders / Q000209:etiology; D009431:Neural Conduction; D010265:Paraproteinemias / Q000150:complications; D010951:Plasma Exchange; D011115:Polyneuropathies / Q000276:immunology / Q000628:therapy*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000628:therapy
D007136:Immunoglobulins; D007166:Immunosuppressive Agents